1. Prevalence of Neutralizing Autoantibodies Against Type I Interferon in a Multicenter Cohort of Severe or Critical COVID-19 Cases in Shanghai.
- Author
-
Shi D, Chen J, Zhao M, Tang Y, Zhao C, Jin Y, Tian D, Liao Y, Wang X, Wang W, Fan X, Yi Z, Chen X, and Ling Y
- Subjects
- Aged, Humans, Male, Autoantibodies, SARS-CoV-2, Prevalence, China epidemiology, Antibodies, Neutralizing, Antiviral Agents, COVID-19 epidemiology, Interferon Type I
- Abstract
Objective: We sought to explore the prevalence of type I interferon-neutralizing antibodies in a Chinese cohort and its clinical implications during the Omicron variant wave of SARS-CoV-2., Methods: Type I interferon (IFN) autoantibodies possessing neutralizing capabilities were identified using luciferase assays. The capacity of the autoantibodies for in vitro interference with antiviral activity of IFN was assessed by using a SARS-CoV-2 replicon system. An analysis of the demographic and clinical profiles of patients exhibiting neutralizing antibodies was also conducted., Results: In this cohort, 11.8% of severe/critical cases exhibited the existence of type I IFN-neutralizing antibodies, specifically targeting IFN-α2, IFN-ω, or both, with an elderly male patient tendency. Notably, these antibodies exerted a pronounced inhibitory effect on the antiviral activity of IFN against SARS-CoV-2 under controlled in vitro conditions. Furthermore, a noteworthy correlation was discerned between the presence of these neutralizing antibodies and critical clinical parameters, including C-reactive protein (CRP) levels, D-dimer levels, and lymphocyte counts., Conclusion: The presence of type I IFN-neutralizing antibodies is a pervasive risk factor for severe/critical COVID-19 in the Chinese population., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF